Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Kevin J. Curran"'
Autor:
Eric L. Smith, Brigitte Senechal, Craig S. Sauter, Jolanta Stefanski, Fang Du, Prasad S. Adusumilli, Susan F. Slovin, Ling-bo Shen, Devanjan S. Sikder, Jagrutiben Chaudhari, Kevin J. Curran, Renier J. Brentjens, Keyur Thummar, Yongzeng Wang, Melanie Hall, Xiuyan Wang, Isabelle Riviere, Roisin E. O'Cearbhaill, Mark B. Geyer, Sham Mailankhody, Mingzhu Zhu, Jae H. Park, Paridhi Gautam, Jinrong Qu, Oriana Borquez-Ojeda
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss, Pp 377-387 (2021)
With the US Food and Drug Administration (FDA) approval of four CD19- and one BCMA-targeted chimeric antigen receptor (CAR) therapy for B cell malignancies, CAR T cell therapy has finally reached the status of a medicinal product. The successful manu
Autor:
Brigitte Senechal, Mark B. Geyer, Marco L. Davila, Kevin J. Curran, Mithat Gonen, Mikhail Roshal, Isabelle Riviere, Michel Sadelain, Peter Maslak, Jessica Flynn, Kitsada Wudhikarn, Claudia Diamonte, Renier J. Brentjens, Jae H. Park, Xiuyan Wang, Elizabeth Halton
Publikováno v:
Blood
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult
Autor:
Audrey Mauguen, Snehit Prabhu, Christine L Phillips, Kevin J. Curran, Michael Kunicki, Prakash Satwani, Theodore W. Laetsch, Rachel Wilcox, Muna Qayed, Vasant Chinnabhandar, Crystal L. Mackall, Steven P. Margossian, Michael R. Verneris, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Julie-An An Talano, Emily Egeler, Gary Doug Myers, A. Yasemin Goksenin, Amy Moskop, Cara A Rabik, Holly L Pacenta, Amy K. Keating, Jenna Rossoff, Christa Krupski, Heather E. Stefanski, Patrick A. Brown, Nicole Karras, Jaap Jan Boelens, Sharon Mavroukakis, Liora M. Schultz
Publikováno v:
Blood advances, vol 6, iss 7
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab5a5590ca98bdc6c2ccd6b052b9feb
https://escholarship.org/uc/item/6xt142fk
https://escholarship.org/uc/item/6xt142fk
Autor:
Michael Kunicki, Sharon Mavroukakis, Cara A Rabik, Christine L Phillips, Amy K. Keating, Jenna Rossoff, Christa Krupski, Rachel Wilcox, Amy Moskop, Adam Lane, Nicole Karras, Kevin J. Curran, A. Yasemin Goksenin, Crystal L. Mackall, Vasant Chinnabhandar, Emily Egeler, Heather E. Stefanski, Michelle L. Hermiston, Julie-An An Talano, Theodore W. Laetsch, Gary Doug Myers, Prakash Satwani, Snehit Prabhu, Christina Baggott, Steven P. Margossian, Patrick A. Brown, Muna Qayed, Vanessa A Fabrizio, Holly L Pacenta, Michael R. Verneris, Liora M. Schultz
Publikováno v:
Blood Advances
Key Points CD19 CAR therapy for R/R EM disease, particularly CNS, offers a beneficial option with similar toxicity and survival to BM disease.There was no increased cytokine release syndrome or neurotoxicity in patients with R/R EM disease, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5643a68fa7ec55f29728456a9d6f1876
https://escholarship.org/uc/item/1g83m8ch
https://escholarship.org/uc/item/1g83m8ch
Autor:
Karl S. Peggs, William Y. Go, Noelle V. Frey, Jennifer N. Brudno, Elena Mead, Bianca Santomasso, Rebecca Gardner, Steven Z. Pavletic, Marcelo C. Pasquini, Sattva S. Neelapu, Stephan A. Grupp, Kevin J. Curran, Frederick L. Locke, Daniel W. Lee, Cameron J. Turtle, Marcel R.M. van den Brink, Krishna V. Komanduri, Jae H. Park, Armin Ghobadi, Marcela V. Maus, John F. DiPersio, Lamis K. Eldjerou
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:625-638
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment ofpatients up to age 2
Autor:
Marcelo C. Pasquini, Javed Khan, Carlos Sandi, Agne Taraseviciute, Allison Barz Leahy, Timothy S. Olson, Haneen Shalabi, Pamela L. Wolters, Lori Wiener, Rebecca Gardner, Christine Duncan, Joshua A. Hill, Veronique Nussenblatt, Nirali N. Shah, Stephan A. Grupp, Hao-Wei Wang, Kevin J. Curran, Michael A. Pulsipher, Juliane Gust, Theodore W. Laetsch, Colleen Annesley
Publikováno v:
Nat Rev Clin Oncol
As clinical advances with chimeric antigen receptor (CAR) T cells are increasingly described and the potential for extending their therapeutic benefit grows, optimizing the implementation of this therapeutic modality is imperative. The recognition an
Autor:
Renier J. Brentjens, K. Hosszu, Terence J. Purdon, Michel Sadelain, M. Lakkaraja, Brigitte Senechal, D. Mcavoy, T. Auchincloss, Audrey Mauguen, Kevin J. Curran, Bianca Santomasso, Y. Khakoo, J. Park, Isabelle Riviere, Elizabeth Klein, Jaap-Jan Boelens
Publikováno v:
Cytotherapy. 23:S99-S100
Autor:
Kevin J. Curran, Victoria Szenes
Publikováno v:
Seminars in oncology nursing. 35(5)
Objective To provide an overview of chimeric antigen receptor (CAR) T cell therapy for pediatric patients with relapsed or refractory malignancy and the associated toxicities. Data Sources Research articles, reviews, clinical trial information. Concl
Autor:
Kevin J. Curran, Vanessa A Fabrizio
Publikováno v:
Best Pract Res Clin Haematol
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment for both pediatric and adult patients with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL). Clinical trial results across multiple institutions with
Autor:
Kevin J. Curran, Renier J. Brentjens, Dayenne G. van Leeuwen, Andrea V. Lopez, Nicholas F. Kuhn, Terence J. Purdon, Anthony F. Daniyan
Summary Chimeric antigen receptor (CAR) T cells provide great efficacy in B cell malignancies. However, improved CAR T cell therapies are still needed. Here, we engineered tumor-targeted CAR T cells to constitutively express the immune-stimulatory mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75af8148e42c533aed269ec2a7e97ff9
https://europepmc.org/articles/PMC6428219/
https://europepmc.org/articles/PMC6428219/